Substandard medicines contribute to treatment failure and spread
antimicrobial resistance. Erin Wilhelm describes what we can do to stop it.
Carly Ching and Muhammad Zaman discuss their new research on how substandard antibiotics contribute to antimicrobial resistance, and the impact of COVID-19.
Matthew Hassett and Paul Roepe share the results of their USP Quality Institute research on the spread of antimicrobial resistance in Southeast Asia.
Bacteria and other microbes becoming resistant to treatment by antibiotics and other lifesaving drugs is a serious and growing public health threat. Antimicrobial resistance is a result, in part, of the prevalence of substandard and falsified medicines.
USP Quality Institute research is evaluating the link between poor-quality medicines and antimicrobial resistance and helping identify solutions to this pressing global health problem.
The threat of bacteria and other microbes becoming resistant to treatment by antibiotics and other lifesaving drugs is a serious concern and public health threat. USP is working to help address this issue.